TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02957500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore® (adhesion barrier)
Study: NCT03350360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Training
Description: Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison Task
Description: Neutral- neutral stimuli prior to response task
Study: NCT03966755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UFA dietary recommendations
Description: The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
Study: NCT00821470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: core decompression procedure only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: core decompression procedure only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow implantation into the necrotic lesion
Study: NCT03096327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
Study: NCT01310426

Intervention type: OTHER
Intervention: 3D transperineal Ultrasound
Description: 3D transperineal Ultrasound after vaginal delivery
Study: NCT00060333

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02764684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
Study: NCT04180566

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound Examination
Description: Includes a regular growth ultrasound examination.

Intervention type: OTHER
Group type: OTHER
Intervention: Antenatal Testing (biophysical profile)
Description: Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
Study: NCT03612765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push-Pull-Hold Program
Description: Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
Study: NCT02337634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milk Thistle
Description: Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
Study: NCT04877236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Sun Medical Brace
Description: All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board.
Study: NCT01858649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
Study: NCT03221309

Intervention type: OTHER
Intervention: Evaluate model of care for HCV-infected adults with on-going opioid misuse
Description: Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
Study: NCT03306329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNS-7801 (low-dose)
Description: DNS-7801 (low-dose) tablets administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNS-7801 (high dose)
Description: DNS-7801 (high dose) tablets administered once daily.
Study: NCT04437524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
Study: NCT00743639

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intramyocardial bone marrow stem cells implantation
Description: Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days.
Study: NCT02744963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free and convenient medicine access
Study: NCT02300922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody TF2
Description: injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90-Y-IMP-288
Description: Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In-IMP-288
Description: Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
Study: NCT02573142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bull City Healthy and Fit
Description: Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Clinic
Description: Clinic-only model of care including clinical care and educational materials
Study: NCT04506073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: 1 dose is 10 X 10\^6 MSC/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: 1 dose is 10 X 10\^6 MSC/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
Study: NCT00352027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin®
Description: Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrogen Mustard
Description: Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Study: NCT03789929

Intervention type: BEHAVIORAL
Intervention: The Emotional Backpack
Description: In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.

Intervention type: BEHAVIORAL
Intervention: Feelings as Powers
Description: In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
Study: NCT01930201

Intervention type: PROCEDURE
Intervention: Caudal epidural block

Intervention type: OTHER
Intervention: General anesthesia

Intervention type: OTHER
Intervention: General anesthesia
Study: NCT02686502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
Study: NCT03306329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered once daily
Study: NCT00443820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) once daily for 24 weeks
Study: NCT00451906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: As prescribed
Study: NCT01829776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
Study: NCT03581656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChordArt System
Description: The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
Study: NCT01420289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High pressure intermittent pneumatic compression (HPIPC)
Description: Apply therapy for 45 minutes twice daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Excercise
Description: Treadmill walking 45 minutes once daily
Study: NCT00975533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tantalus
Description: The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
Study: NCT00451906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: 15 mg/kg IV on Day 1 of each 3 week cycle
Study: NCT02542202

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study: NCT00352027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV on Days 1 and 2 of weeks 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO every other day of weeks 1-12.
Study: NCT01733446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of High Frequency Jet Ventilation (HFJV)
Description: In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
Study: NCT01478321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01869296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: higher flow rates
Description: higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower flow rates
Description: lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
Study: NCT04702477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
Study: NCT03344172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab
Description: Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
Description: Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
Study: NCT00450073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol (vitamin D2)
Description: 50,000 IU weekly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sperti Del Sol Lamp
Description: 5 times a week for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 50,000 IU weekly
Study: NCT00813891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
Study: NCT00352027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
Study: NCT00842829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet (FBT)
Description: FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
Study: NCT02551419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic drink
Description: 6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
Study: NCT01471210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab (BMS-663513)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab (BMS-663513)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab (BMS-663513)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab (BMS-663513)
Study: NCT03468582

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 123I radiolabeled 3BNC117
Description: 123I radiolabeled 3BNC117
Study: NCT04378231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension
Description: dry suspension of amoxicillin clavulanate potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension
Description: dry suspension of amoxicillin clavulanate potassium
Study: NCT02690649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Messaging (Non-Procedural)
Description: Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
Study: NCT03802045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3.